– Collaboration will simplify providers' and patients' access to discrete test results that can inform more precise, personalized medicine – SAN FRANCISCO, March 21, 2023 /PRNewswire/ -- Invitae (NVTA ...
A new survey released today shows 73 percent of Americans are aware of genetic testing for hereditary cancers – a significant increase over just a few years ago. Previous research found that in 2010 ...
SAN FRANCISCO, March 15, 2023 /PRNewswire/ -- Invitae (NVTA) (NYSE: NVTA), a leading medical genetics company, today announced seven studies, including one oral presentation and six posters, to be ...
Invitae Corporation (NYSE: NVTA), a genetic information company, has announced that it has more than doubled the size of its genetic testing platform to include more than 600 genes and will begin ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Invitae cut about 1,000 jobs ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. San Francisco genetic testing firm Invitae succeeded this ...
Eli Lilly's treatment for early Alzheimer's is expected to be blocked for use by Britain's National Health Service (NHS), the Telegraph reported on Friday. Macro Matterscategory US new home sales rise ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback